APHS’ Q4FY22 EBITDA was 6% lower than our estimates largely on slower hospital traction. While another delay in Healthco fund-raise is a dampener, execution stays impressive and APHS is witnessing healthy demand tailwinds across all segments. Post a 38% fall from its 52-week high, valuations are attractive. For the hospital segment, CMP implies a <16X […]